Page last updated: 2024-10-25

cilostazol and Cancer of Pituitary

cilostazol has been researched along with Cancer of Pituitary in 2 studies

Research Excerpts

ExcerptRelevanceReference
"Cilostazol-induced increase in I(K(Ca)) was suppressed by paxilline (1 microM) but not glibenclamide (10 microm), dequalinium dichloride (10 microM), or beta-bungarotoxin (200 nM)."1.32Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells. ( Huang, MH; Liu, SI; Wu, SN, 2004)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wu, SN2
Liu, SI1
Huang, MH1
Lin, MW1
Wu, AZ1
Ting, WH1
Li, CL1
Cheng, KS1

Other Studies

2 other studies available for cilostazol and Cancer of Pituitary

ArticleYear
Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells.
    Endocrinology, 2004, Volume: 145, Issue:3

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Action Potentials; Adenoma; Adenosine; Adenosine Diphosphate; A

2004
Changes in membrane cholesterol of pituitary tumor (GH3) cells regulate the activity of large-conductance Ca2+-activated K+ channels.
    The Chinese journal of physiology, 2006, Feb-28, Volume: 49, Issue:1

    Topics: Action Potentials; Animals; Apamin; beta-Cyclodextrins; Caffeic Acids; Calcium; Cholesterol; Cilosta

2006